PRMT5 and mantle cell lymphoma: PRMT5 inhibition significantly reduced tumor volume in an MCL and a DLBCL patient-derived xenograft and Z-138 xenograft models without inducing toxicity, as shown by the maintenance of the animal’s weight (Supplementary Fig. 1D).